Am J Transplant, Volume 16, Suppl 3 Archives - Page 124 of 180 - ATC Abstracts

2016 American Transplant Congress
Modification of DC Phenotype and Function via Targeted Porous Silicon Nanoparticles.
S. Stead,¹ S. McInnes,² S. Kireta,³ P. Rose,¹ D. Rojas-Canales,³ S. Jesudason,³ S. Grey,⁴ R. Carroll,³ N. Voelcker,² P. Coates.^1,3
¹School of Medicine, University of Adelaide, Adelaide, Australia; ²Future Industries Institute, University of South Australia, Adelaide, Australia; ³CNARTS, Royal Adelaide Hospital, Adealide, Australia; ⁴Transplantation Immunology, Garvan Institute of Medical Research, Sydney, Australia.
Aims: Dendritic cells (DC) are the most potent antigen-presenting cell and are fundamental in the establishment of transplant tolerance. Targeting DC via the DC-SIGN receptor…
2016 American Transplant Congress
Three-Year Graft Loss Risk in Kidney Transplants: Dynamic Patient Level Data Improve Predictive Efficacy.
T. Srinivas, J. Zhang, Z. Su, D. Taber, J. Marsden, K. Reilly, D. Northrup, J. Long, L. Lenert, W. Moran, P. Mauldin.
MUSC, Charleston, SC.
Background: Predictive models in kidney transplantation using national data (UNOS, SRTR) lack longitudinal patient level data, limiting accuracy. Adding patient level data capturing dynamic clinical…
2016 American Transplant Congress
Outcomes Associated with Carbapenem-Resistant Enterobacteriaceae Infection After Solid Organ Transplantation in a Multicenter Study.
S. Huprikar,¹ L. Casner,¹ L. Camera Pierrotti,² A. Nellore,³ R. Madan,⁴ J. Garcia-Diaz,⁵ S. Jacobs,⁶ D. Lee,⁷ W. Trindade Clemente,⁸ G. Alangaden,⁹ R. La Hoz,¹⁰ N. Theodoropoulos,¹¹ M. Miceli,¹² G. Santoro-Lopes,¹³ D. Banach,¹⁴ D. Simon,¹⁵ G. Patel.¹
¹Mount Sinai, New York; ²Univ of Sao Paulo, Sao Paulo, Brazil; ³UAB, Birmingham; ⁴Albert Einstein, Bronx; ⁵Oschner, New Orleans; ⁶Cornell, New York; ⁷Drexel, Philadelphia; ⁸Univ Federal de Minas Gerais, Belo Horizonte, Brazil; ⁹Henry Ford, Detroit; ¹⁰UT Southwestern, Dallas; ¹¹Ohio State, Columbus; ¹²U of Michigan, Ann Arbor; ¹³Federal Univ of Rio de Janeiro, Rio de Janeiro, Brazil; ¹⁴Yale, New Haven; ¹⁵Rush, Chicago.
BackgroundCarbapenem-resistant Enterobacteriaceae infection (CREI) is associated with poor outcomes in solid organ transplant (SOT) recipients but most reports are single center experiences.MethodsPatients who underwent SOT…
2016 American Transplant Congress
Short-Term Post-Donation Renal Function in Living Kidney Donors.
L. Fahmy, A. Massie, A. Muzaale, S. Sandal, E. Chow, D. Segev.
JHU, Baltimore.
Previous single-center studies of post-donation estimated glomerular filtration rate (eGFR) in living kidney donors were limited by small sample size and lack of generalizability. The…
2016 American Transplant Congress
Utilization and Post-Transplant Outcomes Associated with Hepatitis C+ Donor Kidneys in the Advent of Direct-Acting Antivirals.
M. Bowring, L. Kucirka, A. Massie, X. Luo, M. Sulkowski, D. Segev, C. Durand.
JHU, Baltimore.
The introduction of interferon-free direct-acting antivirals(DAAs) in December 2013 dramatically improved outcomes for individuals with Hepatitis C. The impacts of these therapies on utilization and…
2016 American Transplant Congress
99% and 100% CPRA Patients Since KAS: A Substantial Increase in Transplants with Strong Evidence of a Bolus Effect.
A. Kucheryavaya,¹ M. Aeder,² N. Turgeon,³ D. Klassen,¹ D. Stewart.¹
¹UNOS, Richmond, VA; ²Univ Hosp Case Med Ctr, Cleveland, OH; ³Emory Univ Hosp, Atlanta, GA.
Background: The Kidney Allocation System (KAS), implemented on 12/4/14, increased allocation priority for candidates with CPRA of 99-100%. Analyses performed on behalf of the OPTN…
2016 American Transplant Congress
Short Term Changes in HRQOL Following Kidney Transplantation.
I. Olorundare, H. Ying, M. McAdams-DeMarco, D. Segev.
JHU, Baltimore.
Health-Related Quality of Life (HRQOL) is a patient-centered outcome that measures the impact of a disease and its treatment. This is particularly relevant to those…
2016 American Transplant Congress
Everolimus Plus Reduced-Exposure Cyclosporin versus Mycophenolic Acid Plus Cyclosporin: Seven-Year Follow-Up of Australia and New Zealand Kidney Transplant Recipients in the A2309 Study.
S. Chadban,¹ H. Pilmore,² G. Russ,³ J. Kanellis,⁴ S. Campbell,⁵ P. O'Connell,⁶ W. Lim,⁷ M. Lutherborrow,⁸ N. Kurstjens,⁸ R. Walker.⁹
¹Renal Medicine, Royal Prince Alfred Hospital, Sydney, Australia; ²Auckland Renal Transplant, Auckland City Hospital, Auckland, New Zealand; ³Central Northern Adelaide Ranel and Transplantation Service, Royal Adelaide Hospital, Adelaide, Australia; ⁴Renal Medicine, Monash Medical Centre, Melbourne, Australia; ⁵University of Queensland, Princess Alexandra Hospital, Queensland, Australia; ⁶Renal Medicine, Westmead Hospital, Sydney, Australia; ⁷WA Liver and Kidney Transplant Service, Sir Charles Gairdner Hospital, Perth, Australia; ⁸Novartis Pharmaceuticals, Sydney, Australia; ⁹Renal Medicine, Alfred Hospital, Melbourne, Australia.
A2309 was a 2-year, phase III randomized controlled trial evaluating the effect on graft and patient outcomes of three groups:1.5mg everolimus plus low exposure cyclosporine…
2016 American Transplant Congress
Better Never Than Late: Differences in Outcomes and Risk Factors for Early and Late Rejection After Kidney Transplantation.
A. Liu, N. Sarabu, A. Joshua.
Medicine, University Hospitals Case Medical Center, Cleveland, OH.
Background: Late acute rejection (AR) is associated with inferior outcomes relative to early AR after kidney transplantation. We sought to examine the differences in risk…
2016 American Transplant Congress
Fc Receptor Binding Assay for Functional Assessment of HLA Antibodies: Initial Clinical Validation.
E. Woodle, A. Girnita.
U of Cincinnati, Cincinnati.
Functional assessment of HLA antibodies (Abs) has historically been limited to complement-based assays, which have known limitations. Moreover, HLA Abs mediate injury by complement-independent mechanisms,…